Industry Relations Council

APHON Industry Relations Council (IRC) participation is available to organizations and companies that support the goals and mission of APHON. Participating organizations have their choice of two involvement levels — Premier and Associate — each with its own benefit structure and exclusive opportunities to engage with APHON’s audience.

IRC BENEFITS 

Premier Level Member

121 Seaport Blvd Boston, MA 02210 | Learn More about Alexion

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for more than 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. Alexion focuses research efforts on novel molecules and targets that include the complement cascade, and development efforts in hematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 70 countries.

Alexion is committed to helping your patients access the care they need. OneSource™ is a free, personalized patient support program offered by Alexion. Whether your patient is newly diagnosed or has had their condition for some time, our specialists are available for patients and their caregivers. We can help them make sense of their health insurance coverage, answer questions about treatment options and connect them to community resources. We’re committed to helping your patients start and stay on track with their prescribed Alexion treatment.

One Amgen Center Drive Thousand Oaks, CA 91320 | Learn More about Amgen

While science continues to explore potential cures, every cancer journey is full of challenges from many angles. We can do more. Amgen Oncology advances All Angles of Care by delivering a spectrum of cancer treatment options, from transformative medicines to outcome-enabling solutions such as supportive care and biosimilars.

200 Pier Four Blvd Boston, MA 02210 | Learn More about Servier

We are a U.S. based biotech company serving patients and caregivers in oncology. Our deep commitment to patients is fundamental to our culture. We consistently engage with patients, caregivers, families, and organizations to fully understand the patient communities’ needs. We can expand our knowledge on patient needs each day through ongoing partnerships with patient experts and advocacy groups. Through our Patient Engagement Program, acute lymphoblastic leukemia patients and families can access Servier’s guidance and resources throughout the treatment and recovery process. At Servier, we know navigating an acute lymphoblastic leukemia diagnosis and managing a multi-agent chemotherapeutic regimen can be overwhelming for patients and caregivers.  Our Patient Engagement Managers can help. Former acute lymphoblastic leukemia patients and caregivers themselves, they work one-on-one with patients and their families, answering questions, providing emotional support, and directing them to key resources and support services. Servier also offers a Free Product Program; qualifying US citizens and having a financial need may be able to receive prescribed Servier products at no cost. Our Patient Advocacy Team is proud to work with organizations that share our goal to improve patient outcomes for those affected by acute lymphoblastic leukemia. Patient organizations provide valuable educational information and resources that improve the lives of those facing cancer.

Associate Level Member

2000 Sierra Point Parkway, Suite 501 Brisbane, CA 94005 | Learn More about Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan, Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments. The Company’s pipeline includes tovorafenib (OJEMDA™), pimasertib, and DAY301.